Is monthly retreatment with intravitreal bevacizumab (Avastin&reg;) necessary in neovascular age-related macular degeneration?

Nicola G Ghazi, Tyler Q Kirk, Robert M Knape, James S Tiedeman, Brian P ConwayDepartment of Ophthalmology, University of Virginia Health System, Charlottesville, VA, USAPurpose: To report our short-term experience with bevacizumab in neovascular age-related macular degeneration (AMD) and recommend a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nicola G Ghazi, Tyler Q Kirk, Robert M Knape, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/8fcfeaad584e4ce9ab50cf2d60b2a22e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8fcfeaad584e4ce9ab50cf2d60b2a22e
record_format	dspace
spelling	oai:doaj.org-article:8fcfeaad584e4ce9ab50cf2d60b2a22e2021-12-02T02:37:51ZIs monthly retreatment with intravitreal bevacizumab (Avastin&reg;) necessary in neovascular age-related macular degeneration?1177-54671177-5483https://doaj.org/article/8fcfeaad584e4ce9ab50cf2d60b2a22e2010-04-01T00:00:00Zhttp://www.dovepress.com/is-monthly-retreatment-with-intravitreal-bevacizumab-avastinreg-necess-a4221https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Nicola G Ghazi, Tyler Q Kirk, Robert M Knape, James S Tiedeman, Brian P ConwayDepartment of Ophthalmology, University of Virginia Health System, Charlottesville, VA, USAPurpose: To report our short-term experience with bevacizumab in neovascular age-related macular degeneration (AMD) and recommend a new treatment strategy.Methods: Retrospective chart review of 29 consecutive patients receiving 1.25 mg of intravitreal bevacizumab for AMD and completing 12 weeks of follow up. Outcome measures were best corrected visual acuity (BCVA) and optical coherence tomography (OCT) central macular thickness. Injections were repeated if no further improvement was observed.Results: Twenty-nine eyes of 29 patients were included. The average BCVA improved from 20/148 at baseline to 20/106 at twelve weeks (P = 0.041). Of the 29 eyes, 25 (86.2%) had stable or improved BCVA. Average mean central macular thickness measured by OCT improved from 351 &mu;m at baseline to 278 &mu;m at 12 weeks (P = 0.003). Stabilization of vision and improved OCT central macular thickness were maintained for at least eight weeks following only a single injection in the majority of eyes. During the three months of follow up, only five eyes (17.2%) required repeat injections, with only three (10.3%) requiring retreatment at eight weeks and none at four weeks. No significant ocular or systemic side effects were observed. Conclusion: This short-term data suggests that bevacizumab appears to be a safe and effective treatment for neovascular AMD. Injections as frequent as every month do not appear to be necessary since initial treatment effect appears to be maintained for at least eight weeks in almost all of our patients.Keywords: retina, Avastin&reg;, bevacizumab, neovascular age-related macular degeneration, AMD Nicola G GhaziTyler Q KirkRobert M Knapeet alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 307-314 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Nicola G Ghazi Tyler Q Kirk Robert M Knape et al Is monthly retreatment with intravitreal bevacizumab (Avastin&reg;) necessary in neovascular age-related macular degeneration?
description	Nicola G Ghazi, Tyler Q Kirk, Robert M Knape, James S Tiedeman, Brian P ConwayDepartment of Ophthalmology, University of Virginia Health System, Charlottesville, VA, USAPurpose: To report our short-term experience with bevacizumab in neovascular age-related macular degeneration (AMD) and recommend a new treatment strategy.Methods: Retrospective chart review of 29 consecutive patients receiving 1.25 mg of intravitreal bevacizumab for AMD and completing 12 weeks of follow up. Outcome measures were best corrected visual acuity (BCVA) and optical coherence tomography (OCT) central macular thickness. Injections were repeated if no further improvement was observed.Results: Twenty-nine eyes of 29 patients were included. The average BCVA improved from 20/148 at baseline to 20/106 at twelve weeks (P = 0.041). Of the 29 eyes, 25 (86.2%) had stable or improved BCVA. Average mean central macular thickness measured by OCT improved from 351 &mu;m at baseline to 278 &mu;m at 12 weeks (P = 0.003). Stabilization of vision and improved OCT central macular thickness were maintained for at least eight weeks following only a single injection in the majority of eyes. During the three months of follow up, only five eyes (17.2%) required repeat injections, with only three (10.3%) requiring retreatment at eight weeks and none at four weeks. No significant ocular or systemic side effects were observed. Conclusion: This short-term data suggests that bevacizumab appears to be a safe and effective treatment for neovascular AMD. Injections as frequent as every month do not appear to be necessary since initial treatment effect appears to be maintained for at least eight weeks in almost all of our patients.Keywords: retina, Avastin&reg;, bevacizumab, neovascular age-related macular degeneration, AMD
format	article
author	Nicola G Ghazi Tyler Q Kirk Robert M Knape et al
author_facet	Nicola G Ghazi Tyler Q Kirk Robert M Knape et al
author_sort	Nicola G Ghazi
title	Is monthly retreatment with intravitreal bevacizumab (Avastin&reg;) necessary in neovascular age-related macular degeneration?
title_short	Is monthly retreatment with intravitreal bevacizumab (Avastin&reg;) necessary in neovascular age-related macular degeneration?
title_full	Is monthly retreatment with intravitreal bevacizumab (Avastin&reg;) necessary in neovascular age-related macular degeneration?
title_fullStr	Is monthly retreatment with intravitreal bevacizumab (Avastin&reg;) necessary in neovascular age-related macular degeneration?
title_full_unstemmed	Is monthly retreatment with intravitreal bevacizumab (Avastin&reg;) necessary in neovascular age-related macular degeneration?
title_sort	is monthly retreatment with intravitreal bevacizumab (avastin&reg;) necessary in neovascular age-related macular degeneration?
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/8fcfeaad584e4ce9ab50cf2d60b2a22e
work_keys_str_mv	AT nicolagghazi ismonthlyretreatmentwithintravitrealbevacizumabavastinampregnecessaryinneovascularagerelatedmaculardegeneration AT tylerqkirk ismonthlyretreatmentwithintravitrealbevacizumabavastinampregnecessaryinneovascularagerelatedmaculardegeneration AT robertmknape ismonthlyretreatmentwithintravitrealbevacizumabavastinampregnecessaryinneovascularagerelatedmaculardegeneration AT etal ismonthlyretreatmentwithintravitrealbevacizumabavastinampregnecessaryinneovascularagerelatedmaculardegeneration
_version_	1718402302583242752

Is monthly retreatment with intravitreal bevacizumab (Avastin&amp;reg;) necessary in neovascular age-related macular degeneration?

Ejemplares similares

Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?